Creabilis Sa
LUXEMBOURG, October 4, 2011 -
Funds to Advance Development of Creabilis' First-in-Class Products
Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, inflammation and pain, has raised €15 million ($20 million) in a Series B funding round led by Abbott Biotech Ventures.
LUXEMBOURG, August 18, 2011 -
Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, inflammation and pain, announced today the expansion of its senior management team with the appointment of three experienced international pharma executives.
LUXEMBOURG, August 4, 2011 -
Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, inflammation and pain, announces today that Dr David Roblin has been appointed Chief Medical Officer.
Creabilis Announces Positive Phase IIa Results for TrkA Kinase Inhibitor CT327 in Psoriasis Vulgaris
LUXEMBOURG, March 10, 2011 - Creabilis SA, a clinical stage European biotechnology company addressing
unmet medical needs in dermatology, today announced positive results from its
Phase IIa study of its lead product CT327 in psoriasis vulgaris.
LUXEMBOURG, December 15, 2010 - Creabilis SA, a clinical stage European biotechnology company
addressing unmet medical needs in dermatology, today announced positive
results in the Phase IIa study of its lead product CT327 in atopic
dermatitis.
